New vaccine combo shows promise in advanced cancers
NCT ID NCT05077709
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a new cancer vaccine (IO102-IO103) combined with the immunotherapy drug pembrolizumab as a first treatment for people with advanced lung, head/neck, or bladder cancer that had spread. The study enrolled 63 participants to see if the combination is safe and effective at shrinking tumors. Results will help determine if this approach deserves further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IO102-IO103 (a cancer vaccine) combined with pembrolizumab (an immunotherapy drug)
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with these advanced cancers, potentially improving response rates and delaying disease progression.
- What could go wrong
- This is an early-phase trial with only 63 participants, so results may not apply broadly. The combination may cause immune-related side effects, and not all patients may benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Guys and St Thomas Hospital
London, United Kingdom
-
Hospital Clínico Lozano Blesa
Zaragoza, Zaragoza, 50009, Spain
-
Hospital Clínico Universitario de Valencia
Valencia, Valencia, Spain
-
Hospital Universitari de Girona Doctor Josep Trueta
Girona, 17007, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Virgen Macarena
Seville, Sevilla, 41009, Spain
-
Hospital Universitario Virgen de la Victoria
Málaga, 29010, Spain
-
Hospital Vall d'Hebron
Barcelona, 08035, Spain
-
Institut Català d'Oncologia (ICO) Badalona (Catalan Institute of Oncology)
Barcelona, 08916, Spain
-
Mid Florida Hematology and Oncology Center
Orange City, Florida, 32763, United States
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
UC Davis Cancer Center
Sacramento, California, 95817, United States
-
University of California San Diego
San Diego, California, 92093, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Toledo Medical Center
Toledo, Ohio, 43614, United States
-
Velindre Cancer Center
Cardiff, CF14 2TL, United Kingdom
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?